Cancer treatment in Sweden - Costs of drugs, inpatient and outpatient care from 1985 to 1996 and cost effectiveness of new drugs

被引:5
|
作者
Tennvall, GR
Karlsson, G
机构
[1] Swedish Inst Hlth Econ, IHE, S-22002 Lund, Sweden
[2] Stockholm Sch Econ, Ctr Hlth Econ, S-11383 Stockholm, Sweden
关键词
D O I
10.1080/028418698430395
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study was carried out to investigate the direct costs for treatment of patients with cancer from 1985 to 1996 in Sweden. and to examine health economic effects of changes in treatment pattern. Material for the study was collected from official statistics and from published health economic evaluations of cancer treatment. Costs for inpatient care decreased during the period, while costs for outpatient care and drugs increased. In total, the direct health care costs for cancer treatment decreased from 1985 to 1996. New drugs registered on the market are often more expensive than the drugs they replace. From a health economic perspective it is not clear, however, that higher drug costs necessarily increase total costs. Further health economic research is needed because many treatment alternatives have not yet been evaluated, and furthermore, because a treatment option can be cost effective in one specific indication but not in another.
引用
收藏
页码:447 / 453
页数:7
相关论文
共 50 条
  • [1] Effects of decentralized responsibility for costs of outpatient prescription drugs on the pharmaceutical cost development in Sweden
    Bergstrom, G
    Andersson, K
    Carlsten, A
    Karlberg, I
    Petzold, M
    Lönnroth, K
    [J]. VALUE IN HEALTH, 2005, 8 (06) : A187 - A187
  • [2] Unbalanced Treatment Costs of Breast Cancer in China: Implications From the Direct Costs of Inpatient and Outpatient Care in Liaoning Province
    Ma, Zihua
    Deng, Gongman
    Meng, Zhaolin
    Ma, Yanan
    Wu, Huazhang
    [J]. INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT, 2022, 11 (09) : 1735 - 1743
  • [3] Costs and Benefits of Branded Drugs: Insights from Cost-Effectiveness Research
    Frech, H. E., III
    Pauly, Mark, V
    Comanor, William S.
    Martinez, Joseph R.
    [J]. JOURNAL OF BENEFIT-COST ANALYSIS, 2022, 13 (02) : 166 - 181
  • [4] IMPACT OF NEW DRUGS AND BIOLOGICALS ON TREATMENT AND COSTS FOR COLORECTAL CANCER
    Shah, N. D.
    Van Houten, H.
    Vermeulen, L.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A56 - A56
  • [5] Impact of New Drugs and Biologics on Colorectal Cancer Treatment and Costs
    Karaca-Mandic, Pinar
    McCullough, Jeffrey S.
    Siddiqui, Mustaqeem A.
    Van Houten, Holly
    Shah, Nilay D.
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2011, 17 (05): : E160 - E168
  • [6] Impact of New Drugs and Biologics on Colorectal Cancer Treatment and Costs
    Karaca-Mandic, Pinar
    McCullough, Jeffrey S.
    Siddiqui, Mustaqeem A.
    Van Houten, Holly
    Shah, Nilay D.
    [J]. JOURNAL OF ONCOLOGY PRACTICE, 2011, 7 (03) : E30S - E37S
  • [7] Continental Divide? The Attitudes of US and Canadian Oncologists on the Costs, Cost-Effectiveness, and Health Policies Associated With New Cancer Drugs
    Berry, Scott R.
    Bell, Chaim M.
    Ubel, Peter A.
    Evans, William K.
    Nadler, Eric
    Strevel, Elizabeth L.
    Neumann, Peter J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) : 4149 - 4153
  • [8] Cost-effectiveness and sustainability of breast cancer screening and new anti-cancer drugs
    Mustacchi, Giorgio
    Generali, Daniele
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (04) : 405 - 408
  • [9] Assessment of the clinical and cost-effectiveness evidence in the reimbursement decisions of new cancer drugs
    Strand, G. Chauca
    Bonander, C.
    Jakobsson, N.
    Johansson, N.
    Svensson, M.
    [J]. ESMO OPEN, 2022, 7 (05)
  • [10] Relationship of Industry Sponsorship to Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer Treatment
    Ruan, Xiulu
    Bumgarner, Gary W.
    Kaye, Alan David
    [J]. JAMA ONCOLOGY, 2016, 2 (04) : 548 - 549